Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Announces Sale of 4 MassArray Systems

NEW YORK, Sept 29 - SEQUENOM (Nasdaq: SQNM) said Friday it had sold four of its MassArray systems for SNP analysis, bringing the company’s installed commercial base of systems to 16.

Sequenom sold the systems to Hitachi (NYSE: HIT), Genetics Institute, Genaissance Pharmaceuticals (Nasdaq: GNSC) and Integrated DNA Technologies. It did not disclose the terms of the deals.

" Hitachi, Genetics Institute, Genaissance and IDT represent four distinct segments in genomics and we are pleased that they have each chosen our MassArray system," Toni Schuh, Sequenom’s President and CEO, said in a statement.

“In particular we are pleased with the opportunity to participate in the emerging Asian biotechnology market through our relationship with Hitachi. This marks our entry into a market with largely untapped growth potential and symbolizes the widespread demand for our technology,” he said.

Hitachi will use Sequenom’s system for its internal SNP marker validation projects while providing genotyping services to the Japanese SNP analysis market, Sequenom said.

Genetics Institute, a unit of Wyeth-Ayerst and a wholly owned subsidiary of American Home Products Corporation (NYSE: AHP), intends to use the system for quality control of oligonucleotides.

Genaissance Pharmaceuticals and Integrated DNA Technologies are both return customers, having previously purchased the MassArray system for SNP analysis and oligonucleotide production, respectively.

Shares of Sequenom were up 2 7/16, or 6.6 percent, at 39 5/8 in morning trading.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.